New company joins share matching service
Entelos Inc joins share matching service on 1st July following delisting from the Aim Market
Entelos is the leader in predictive biosimulation.
Entelos partners with global pharmaceutical and biotechnology organizations worldwide to develop effective new treatments for disease and dramatically reduce the time and cost needed to develop them.
Using its patented PhysioLab technology, Entelos develops dynamic large-scale computer models of human disease. Each PhysioLab platform provides a framework for integrating data (e.g., genomic, proteomic, physiologic, environmental) in the context of a disease or therapeutic area, focusing on understanding and determining clinical responses to potential treatment. Virtual patients are created within this framework to represent real patient subpopulations. Entelos builds and customizes its PhysioLab systems using thousands of peer-reviewed papers, the expertise of its in-house research teams and world-class scientific advisors, and the proprietary information of its collaboration partners.
Using a PhysioLab platform, scientists create virtual patients and simulate experiments and clinical trials in silico (in computer) that could take months or years to do in the laboratory or clinic, increasing the productivity of the drug discovery and development process. Using in silico R&D, Entelos has helped its pharmaceutical partners to:
- Advance compounds and eliminate non-promising programs
- Advance complex clinical strategies to meet efficacy, regulatory, and marketing requirements
- Evaluate in-licensing opportunities
- Save time and reduce patient requirements for clinical trials
- Identify competitive advantages
- Decide which therapeutic indication to pursue for a compound
- Prioritize targets and compounds in a therapeutic area portfolio
Entelos provides integrated expertise in the areas of metabolism and cardiovascular function, immunology and inflammation, and respiratory function. Entelos currently has PhysioLab platforms available for use by multiple customers in the areas of asthma, obesity, type 1 and type 2 diabetes, rheumatoid arthritis, and cholesterol metabolism. The Company is developing models for use in cardiovascular and skin sensitization (skin allergy) applications, and plans to develop PhysioLab systems in such other areas as metabolic syndrome, chronic obstructive pulmonary disease (COPD), osteoporosis, and Alzheimer's disease.
Access to Entelos expertise and technology is available through R&D partnerships, research agreements, licenses, and strategic alliances.
J P Jenkins is part of Rivington Street Holdings.
Rivington Street Corporate Finance is regulated by the Financial Services Authority and is a PLUS Corporate Adviser Member.